SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
A game changing solution for the pharmaceutical industry
The company plans to add 1700 beds by FY27 through the organic route
New leadership team announced at NATHEALTH Annual General Meeting 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The facility will manufacture tablets, capsules, and injections for the oncology segment
Subscribe To Our Newsletter & Stay Updated
